The Trump administration’s steep tariffs on Chinese imports are threatening to further destabilize hospitals’ bottom lines by driving up the cost of essential supplies and exacerbating already fragile ...

The Trump administration aims to change the Medicare Drug Price Negotiation Program in a way that would delay when certain ...

In a new report, the Peterson Center on Healthcare made policy recommendations on reimbursement, access and data collection ...

About a third of small businesses discontinue their health insurance coverage from one year to the next, new research from ...

The FDA laid out a three-year roadmap to phase out animal toxicity testing in drug research. In addition to organoids and lab ...

Sanofi and Regeneron Pharmaceuticals drug Dupixent has won FDA approval for chronic spontaneous urticaria, introducing a new approach to the treatment of this inflammatory skin disorder.

The Trump administration is not finalizing a Biden-era provision that would expand coverage of anti-obesity drugs under ...

UnitedHealth Group took quite the tumble on Thursday and Medicare Advantage troubles seem to largely be at fault. Its shares fell by over 22% after its first quarter earnings on Thursday.

The pairing of two Bristol Myers Squibb immunotherapies is now permitted for the first-line treatment of two types of gastrointestinal cancers, after regulatory decisions handed out this past week ...